ClinicalTrials.gg
CompletedNCT01438710STRATOUpdated Oct 1, 2015Results posted

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

A Phase 3 interventional study of Prograf and LCP-Tacro in Renal Failure and Tremors, sponsored by Veloxis Pharmaceuticals. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-10-01.

Sponsored by Veloxis Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing tacrolimus in Renal Insufficiency — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Renal Insufficiency.

Enrollment
12th of 17
44 · median 50
Started
2011
with 1 other
Phase 3
6 of 17
none open now
Registered
11th of 17
by date
Lead sponsor
8 of 17
Veloxis Pharmaceuticals

Among the 17 studies testing tacrolimus in Renal Insufficiency, this one is the 12th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 3, and was the 11th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 17 studies testing tacrolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About tacrolimus

Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing tacrolimus in Renal Insufficiency as a file.
02

Study summary

This study will evaluate and measure symptomatic hand tremor in stable kidney transplant subjects on Prograf or generic tacrolimus maintenance therapy at baseline (pre-conversion) and following conversion to LCP-Tacro. This study will also evaluate the safety of LCP-Tacro compared with Prograf or generic tacrolimus

Read the detailed description

This is a 2 sequence, open-label, multicenter, prospective Phase 3b clinical study to access drug-induced hand tremors in stable kidney transplant subjects converted from Prograf (tacro-limus, Astellas Pharma US, Inc., Deerfield, IL) or generic tacrolimus twice daily (b.i.d.) to LCP-Tacro tablets (tacrolimus, Veloxis Pharmaceuticals A/S, Horsholm, Denmark) once daily (q.d.). The trial is designed to determine if the test drug LCP-Tacro, is associated with fewer and/or less severe drug-induced hand tremor than observed with Prograf or generic tacrolimus treatment; each therapy is to be concomitantly administered with mycophenolate mofetil (MMF), mycophenolate sodium (MPS), including generic versions of each, and/or prednisone or equivalent as long as doses remain stable during the study. All prophylaxis and other medication will be allowed per standard of care (SOC) in each of the participating sites; no medication that interacts with the pharmacokinetics (PK) of tacrolimus is allowed unless subjects who are recipients of a renal transplant at least 1 month and not more than 5 years prior to enrollment. Following screening, study visits will be conducted over a 2-week treatment period with consists of 1 week of Prograf or generic tacrolimus SOC, and 1 week of LCP-Tacro. Subjects who qualify for extended use of LCP-Tacro can continue LCP-Tacro treatment for additional 2 years. This decision will be made at the discretion of the physician and subject.

03

Conditions studied

  • Renal Failure
  • Tremors
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be able to give written consent
  2. Men and women between 18 and 65 years of age who are recipients of a kidney transplant between 1 month and 5 years prior to the screening date
  3. Subjects with at least one complaint of tremor and existence of postural tremor or action tremor on finger to nose as demonstrated by a score of at least 2 of any of the 4 upper extremity (UE) postural or action and intention assessments on the FTM clinical rating scale
  4. Subjects experiencing symptomatic drug-induced hand tremor associated with use of Prograf or generic tacrolimus as demonstrated by responding "no" to each of the following question: "Did you have a tremor that you noticed prior to starting Prograf or generic tacrolimus for your kidney transplant?", or "Are you aware of a tremor that runs in your family?"
  5. Subjects taking a stable dose of oral Prograf or generic tacrolimus capsules for at least 7 days with trough levels of tacrolimus between 3 to 12 ng/mL. Subjects must maintain tacrolimus trough levels in this range during the 7 day Prograf or generic tacrolimus treatment phase (note that 1 dose adjustment at Study Day 3 [a.m.dose] is allowed for those subjects whose Day0/1 trough level is out of range.
  6. Women of must have a negative serum pregnancy test within 7 days before study start.

Exclusion criteria

Exclusion Criteria:

  1. Recipients of any transplants including organ other than kidney and bone marrow
  2. Subjects with an estimated (eGFR) (MDRD7) \<30mL/min at Screening
  3. Subjects incapable of understanding the purposed and risks of the study, who cannot give written and who are unwilling or unable to comply with study protocol requirements
  4. Pregnant or nursing women
  5. Subjects with who are unwilling/unable to use a double barrier method of
  6. Subjects who were treated with any other agent within 3 months prior to screening
  7. Subjects who are taking drugs that are likely to affect the PK levels of tacrolimus and are not on a stable dose of those medications (see Appendix 1)
  8. Subjects who have essential tremor, Parkinsonism, or tremor from any cause other than tacrolimus-induced tremor;
  9. Subjects who are taking or had been taking any drug within the past 30 days that is well known to promote tremors, including: amiodarone, beta-agonist inhalers (such as albuterol), cyclosporine, lithium, metoclopramide, theophylline, or valproate,or taking within the past 6 months the dopamine blocking agents (antipsychotics) (note, other such medication may be considered on a case-by-case basis at the discretion of the investigator);
  10. Subjects who taking drugs that reduce tremor, and are not on stable doses of the treatment (ie, had not been taking the medication for a minimum of 30 days), including: gabapentin (note, other such medications may be considered on a case-by-case basis at the discretion of the investigator);
  11. Subjects on concurrent with MMD (CellCept) of MPS delayed-release tables (Myfortic), or generic versions of these medication, who have not been on stable doses at least 7 days prior to screening
  12. Subjects receiving prednisone or equivalent at a dose >10 mg per day
  13. Either subjects with an episode of acute rejection requiring treatment or subjects with an episode of -proven or suspected acute rejections that requires treatment within 3 months of screening
  14. Subjects who are being actively treated for cancer (with the exception of non-invasive basal cell or squamous cell) or (HIV)
  15. Subjects with any form of current drug or alcohol abuse
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    LCP-Tacro

    LCP Tacro tables for once daily oral administration

    Drug: LCP-Tacro

  • Experimental
    Prograf

    Tacrolimus capsules for twice daily oral administration

    Drug: Prograf

Interventions

  • Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.

    Also known as: tacrolimus

  • LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.

    Also known as: tacrolimus

06

What researchers measure

Primary outcomes

  1. Evaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro.

    The primary efficacy endpoint is the mean change from baseline (ie Day 7) in the Fahn-Tolosa-Marin Clinical Rating Scale (FTM) for overall tremor score 7 days after (ie, Day 14) LCP-Tacro conversion. The overall FTM score was 0 to 100 where higher scores denoted worst/more severe tremor. Below the mean total score and standard deviation for each treatment is given in addition to the mean change.

    Time frame: 14 days

07

Results

Posted May 8, 2015

Participant flow

First Week of Treatment
Participant flow — First Week of Treatment
MilestoneLCP-TacroPrograf
Started044
Completed041
Not completed03
Second Week of Treatment
Participant flow — Second Week of Treatment
MilestoneLCP-TacroPrograf
Started410
Completed400
Not completed10

Outcome measures

PrimaryEvaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro.

The primary efficacy endpoint is the mean change from baseline (ie Day 7) in the Fahn-Tolosa-Marin Clinical Rating Scale (FTM) for overall tremor score 7 days after (ie, Day 14) LCP-Tacro conversion. The overall FTM score was 0 to 100 where higher scores denoted worst/more severe tremor. Below the mean total score and standard deviation for each treatment is given in addition to the mean change.

Time frame:
14 days
Reported as:
Mean · units on a scale
Evaluation of Hand Tremor and Stable Kidney Transplant Patients When Switched From Prograf to LCP-Tacro.
units on a scaleLCP-Tacro
Total score day 7 (Prograf)25.30 ± 9.472
Total score day 14 (LCP-Tacro)19.96 ± 7.613
Mean change-5.35 ± 7.501
Statistical analysis
  • LCP-Tacro · t-test, 2 sided · p = 0.0048

Adverse events

Collected over Each patient was followed for 25 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LCP-Tacro—0/41 (0%)2/41 (4.9%)
Prograf—1/44 (2.3%)7/44 (15.9%)
Most frequent serious events
Most frequent serious events
EventLCP-TacroPrograf
Incision Site CellulitisInfections and infestations0/411/44
Most frequent other events
Most frequent other events
EventLCP-TacroPrograf
Oedema peripheralGeneral disorders0/413/44
NauseaGastrointestinal disorders2/410/44
Cardiac MurmurInvestigations0/412/44
HyperkalaemiaMetabolism and nutrition disorders0/412/44

Baseline characteristics

44 patients started on the initial one-week treatment on Prograf and 41 were switched to the one-week LCP-Tacro treatment. 40 patients completed the one-week treatment on LCP-Tacro and continued into the 24-months extended use period.

Age, Categorical
Age, Categorical(Participants)Prograf
<=18 years0
Between 18 and 65 years41
>=65 years3
Age, Continuous
Age, Continuous(years)Prograf
Mean47.8 ± 13.68
Sex: Female, Male
Sex: Female, Male(Participants)Prograf
Female10
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prograf
Hispanic or Latino8
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Prograf
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American6
White34
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Prograf
United States44
Target Trough Range (low), ng/mL
Target Trough Range (low), ng/mL(ng/mL)Prograf
Mean5.72 ± 1.912
Target Trough Range (high), ng/mL
Target Trough Range (high), ng/mL(ng/mL)Prograf
Mean8.68 ± 1.863

5 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • Clinical Investigative Site 006
    Los Angeles, California 90057, United States
  • Clinical Investigative Site 1049
    San Diego, California 92123, United States
  • Clinical Investigative Site 007
    Aurora, Colorado 80045, United States
  • Clinical Investigative Site 005
    New Haven, Connecticut 06520, United States
  • Clinical Investigative Site 004
    Lexington, Kentucky 40536, United States
  • Clinical Investigative Site 008
    Minneapolis, Minnesota 55455, United States
  • Clinical Investigative Site 003
    St Louis, Missouri 63110, United States
  • Clinical Investigative Site 002
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Investigative Site 009
    Nashiville, Tennessee 37232, United States
  • Clinical Investigative Site 012
    Dallas, Texas 75246, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Aug 2012 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2011
First posted
Sep 22, 2011
Start
Dec 2011
Primary completionActual
Aug 2012
CompletionActual
Jul 2015
Results first posted
May 8, 2015
Last update
Oct 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01438710
Lead sponsor
Veloxis Pharmaceuticals
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Dec 2011
Primary completion
Aug 2012
Completion
Jul 2015
Results posted
May 8, 2015
Last update
Oct 1, 2015

Study contacts

Alan Glicklich, MD
study director · VP, Clinical Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion